AI use cases in Pharma – explored by the NMPA

China's National Medical Products Administration (NMPA) issued a document on June 18, 2024, detailing 15 high-potential AI application scenarios aimed at addressing critical regulatory challenges in drug regulation. This initiative is designed to integrate AI technology deeply into regulatory processes, streamline operations, enhance resource focus, and empower the regulatory system.

The NMPA is actively planning to introduce AI capabilities across various aspects of medical product regulation, including the classification and management of AI-based medical software. These efforts highlight the potential of AI to transform healthcare by deriving insights from vast amounts of data and supporting medical decision-making. The key insights and advice for drug manufacturers are:

• Embrace AI Integration: Prepare submission materials that are compatible with AI systems to facilitate automated reviews and ensure high data accuracy and consistency.
• Enhance Documentation: Utilize AI for batch documentation management to improve speed, quality, and standardization.
• Support Regulatory Compliance: Ensure comprehensive and accurate data reporting to support AI-driven remote monitoring and risk identification.

Detailed Information on AI use cases in Pharma follows here:

Approval and Review

1. Formal Review

• AI in Review Automation: AI can support the formal review of drug and medical device registrations by automating the review of electronic submission materials. Drug manufacturers should ensure their submission materials are detailed and well-structured to facilitate AI-based reviews.
• Linking Systems: AI can link review systems with administrative approval systems for automatic comparisons of product information and drafting of rejection or correction notices. Maintaining high data accuracy and consistency will be beneficial.

2. Auxiliary Review

• Drug Registrations: AI can structure and extract key information from submissions, significantly reducing review time. Manufacturers are encouraged to prepare submissions that align well with AI's capabilities for text comparison and extraction.
• Cosmetics: AI will analyze product formulations to identify potential risks and ensure compliance. Providing detailed and accurate ingredient information is recommended.

3. Batch Documentation Management

• Automation of Document Processing: AI can automate the identification and processing of batch documents, improving speed, quality, and standardization. Manufacturers should ensure that their documentation processes support AI automation.

Daily Supervision

4. Remote Monitoring

• Risk Identification: AI can analyze safety information, licensee credit, production, and monitoring data to identify risks. Comprehensive and accurate data reporting will enhance AI's effectiveness.

5. On-Site Inspection

• Pre-Inspection Preparation: AI can analyze past reports and company data to suggest inspection focus areas and potential risks. Maintaining detailed historical data will support AI in providing valuable insights.
• Post-Inspection Reporting: AI can aid in drafting inspection reports by using past formats and current inspection records, enhancing report consistency and quality.

6. Auxiliary Sampling Work

• Data Quality Enhancement: AI can extract key information from electronic reports and images, reducing manual entry and improving data consistency and accuracy. High-quality electronic documentation and product images will be beneficial.

7. Auxiliary Investigation and Case Handling

• Case Documentation: AI can assist in generating case documents and analyzing past penalty information. Integrating comprehensive legal and regulatory data into AI systems can standardize and enhance case handling.

8. Drug Vigilance

• Adverse Reaction Evaluation: AI can extract and classify key information from incident reports, significantly improving evaluation efficiency and quality. Thorough and accurate reporting systems for adverse reactions are advised.

9. Online Transaction Supervision

• Risk Analysis Models: AI can analyze historical data and complaints to identify risks, forming risk analysis models and suggesting efficient regulatory plans. Providing detailed transaction data and complying with AI-enhanced supervision plans will optimize regulatory outcomes.

Services to the Public

10. Business Processing and Policy Consultation

• Enhanced Customer Service: AI can speed up response times and improve answer quality for queries and policy consultations. Supporting AI interaction in customer service systems can make business processing more efficient.

11. Instruction Manual Adaptation for the Elderly

• Simplified Communication: AI can adapt drug instructions for easier understanding by the elderly. Preparing comprehensive and accessible information for AI adaptation will improve user experience.

Decision-Supporting Categories

12. Business Data Query

• Automated Queries: AI can revolutionize data queries with conversational interfaces, reducing communication and report preparation costs. Structuring data archives for easy AI integration is recommended.

13. Data Analysis and Prediction

• Trend Identification: AI models can analyze literature and data to identify trends. Maintaining up-to-date and detailed datasets will facilitate accurate AI predictions.

14. Work Plan Research

• Virtual Collaboration: AI models can create virtual roles for brainstorming sessions, offering diverse and insightful ideas. Integrating comprehensive regulatory and business data will enhance AI-supported discussions.

15. Risk Management

• Continuous Monitoring: AI can monitor all stages of drug development and distribution, issuing alerts for non-compliance and predicting future risks. Continuous and detailed data reporting will aid in effective risk management.
• Risk Analysis: AI can identify potential risks throughout the drug lifecycle. Providing detailed records will facilitate precise risk detection and regulatory interventions.

By embracing these AI use cases in Pharma, manufacturers can significantly enhance operational efficiency, ensure compliance, and proactively manage risks in alignment with China's evolving regulatory landscape.

Further information

Read the original announcement on AI use cases in Pharma – explored by the NMPA.

If you would like advice on the best regulatory pathway to market for your pharmaceutical, please contact Cisema.

GET IN TOUCH

🌐 Send us your enquiry📚 Request our whitepapers📣 Sign up for our newsletter